Document is current
Any future updates will be listed below
-
Authors
Jolly, Lucie
Carrasco, Kévin
Salcedo-Magguilli, Margarita
Garaud, Jean-Jacques
Lambden, Simon https://orcid.org/0000-0003-4531-4524
van der Poll, Tom https://orcid.org/0000-0002-9199-5079
Mebazaa, Alexandre
Laterre, Pierre-François
Gibot, Sebastien
Boufenzer, Amir
Derive, Marc
- License Information
-
More Information
Article History
Received: 30 April 2021
Accepted: 26 June 2021
First Online: 19 July 2021
Competing interests
: MD, JJG, and SG are cofounders of Inotrem. LJ, KC, MD, JJG, SL, MSM, and AB are employees of Inotrem SA, a company developing TREM-1 inhibitors. PFL is an advisor of Inotrem SA. AM reports personal fees from Novartis and Orion; grants and personal fees from Adrenomed, Abbott and Roche; and grants from 4TEEN4 outside the submitted work. The other authors declare that they have no other competing interests.
